Lyra Therapeutics, Inc. (LYRA)

0,2767 +0,0155 (+5,93%) Börsenschluss: 04:00PM EDT

Lyra Therapeutics, Inc.

480 Arsenal Way
Watertown, MA 02472
United States
617 393 4600
https://lyratherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 109

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Harlan W. Waksal M.D.	Executive Chairman	210,06k	N/A	1953
Dr. Maria Palasis Ph.D.	CEO, President & Director	942,7k	N/A	1965
Dr. Carmichael S. Roberts Jr., Ph.D.	Co-Founder	N/A	N/A	1969
Mr. Jason Cavalier	CFO, Treasurer & Secretary	464,11k	N/A	1973
Mr. Ray Knox	Vice President of Operations	N/A	N/A	N/A
Mr. Ronan P. O'Brien J.D.	Chief Legal Officer	N/A	N/A	1973
Ms. Vineeta Belanger Ph.D.	Senior Vice President of Clinical Affairs	N/A	N/A	N/A
Dr. Robert Richard Ph.D.	Senior Vice President of Technical Operations	366,74k	N/A	1958
Dr. Robert Kern M.D.	Chief Clinical Advisor	N/A	N/A	N/A
Dr. Richard Nieman M.D.	Chief Medical Officer	606,7k	N/A	1963

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Lyra Therapeutics, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.